reason report
recap opportun data updat come
result reiter financi guidanc provid updat
clinic regulatori progress key program
almost interest attent focus compani late
stage wholli own cancer antibodi schedul
file fda year end compani explain investor
encourag better expect discuss eu
regulatori author potenti file approv base
l-mind expect clearer pictur meet
eu regul summer us side morphosi track
bla submiss year end potenti commerci launch
tafasitamab relaps refractori
line diffus larg cell lymphoma dlbcl meantim
manag activ build commerci capabl
us expect full manufactur suppli launch
addit compani re-affirmed intent start phase
studi front line dlbcl year although design studi
disclos compani report first quarter revenu
came tremfya line consensu
estim expens came larg line consensu
estim sg lower consensu
estim compani report slightli narrow
loss per share compar consensu estim
cash balanc cash cash equival plu
market secur on-going cash flow licens mileston
payment morphosi suffici cash least two year
oper although expect compani rais addit capit
immedi pre-launch period base
chang made model updat price target
adr
dcf analysi discount rate
year price history/av daili volume mil mor gy
compani inform svb leerink llc research
revenu mm
pleas refer page import disclosur price chart analyst certif
price target morphosi mor us adr rate stock
outperform morphosi german biopharmaceut compani long legaci innov
therapeut monoclon antibodi discoveri develop histor morphosi taken
care path build broad portfolio skinni collabor bigger biopharma
compani result potenti low-to-mid singl digit royalti product
collabor final come fruition first reach market
tremfya begin gener royalti morphosi larger basi
compani valu howev morphosi wholly-own
hematolog malign shown impress data single-arm phase ii trial
patient transplant-inelig relaps refractori dlbcl endors
us fda data appear suffici acceler approv
abl gener revenu rang still potenti
develop larger popul sever differ form non-hodgkin lymphoma
nhl import asset mor stock royalti jnj antibodi
psoriasi estim worth today could increas substanti
revenu exce perform product indic royalty-bear
product agreement contribut anoth compani outstand cash reserv
add anoth give total valu per share
revenu beat expens consensu morphosi report revenu
larg tremfya royalti amort prior licens payment
expens came larg line consensu estim sg
significantli lower consensu estim
expens report cost sale base manufactur cost ferment run
requir approv process us total expens
nearli line consensu estim would lower
consensu estim respect apart cost good contribut
compani report slightli narrow loss per share compar consensu
guidanc reiter morphosi reiter prior guidanc revenu
proprietari ebit morphosi state
guidanc exclud potenti signific mileston payment gsk start
phase clinic trial
tafasitamab track year-end bla submiss natur b-mind biomark unclear
morphosi re-affirmed track submit regulatori file tafasitamab treatment
transplant-inelig relapsed/refractori dlbcl end year base l-mind studi
phase l-mind studi design open-label single-arm studi primari
endpoint overal respons rate orr multipl secondari endpoint includ
progression-fre surviv overal surviv os time progress ttp
compani expect present studi top-lin result confer malign
lymphoma icml late june manag extrem optimist tafasitamab
commerci opportun given superior data l-mind although collabor
remain possibl manag seem commit retain full commerci right
tafasitamab us start build us commerci capabl expect
complet b-mind trial continu enrol interim analysi
second half year like import catalyst stock investor sentiment
clear much compani disclos analysi although announc
futil like posit
encourag discuss eu feedback expect
call compani explain recent discuss regulatori offici two potenti
eu rapporteur countri encourag expect suggest compani
could consid file eu singl arm l-mind data rather wait random
b-mind trial might delay proceed year compani provid addit
detail feedback option meet eu regul later summer
multipl pipelin updat beyond compani emphas
pipelin consist program compani re-affirmed plan start
frontlin dlbcl phase combin trial depend data
decid whether proceed pivot phase trial patient commenc
compani remain mysteri natur biomark propos
co-primari endpoint on-going b-mind trial depend interim analysi
trial later year analysi biomarker-bas subset compani may
expand enrol trial patient increas power show
effect bio-mark posit subset expans would delay time final result
apart progress sever
collabor program includ initi pivot trial china compani
ab multipl myeloma mor also plan start exploratori studi
antibodi unnam auto-immun diseas could benefit mileston
initi phase studi gsk rheumatoid arthriti later
morphosi partner novarti also advanc multipl trial inhibitor
atop dermat compani long-term valu boost new trial support
label expans jnj op tremfya ulcer coliti famili adenomat
enter solid cash posit mor report total cash market secur
end quarter current burn rate would suffici cash
two year oper sinc expect compani cash burn increas head
beyond launch reason expect compani rais addit
capit around time approv grow tremfya royalti mileston payment
exist futur partnership could certainli off-set financ requir although
expect compani take conserv approach balanc sheet
model updat pt adr updat morphosi model trend
quarter guidanc provid manag increas forecast
licens revenu reflect higher-than-expect revenu kept
nearli unchang expens decreas estim
increas estim sole driven higher estim sg
expens ep forecast increas lower estim
break-even morphosi base chang slightli decreas
forecast new price target dcf adr
price target mor base dcf methodolog cash flow
termin growth driver forecast royalti tremfya risk-adjust
sale risk-adjust royalti assum discount rate
base compani wacc addit factor mor cash balanc valuat
risk view outlook valuat morphosi includ failur obtain approv
either us ex-u jurisdict base l-mind forecast
product also subject risk better-than-expect market share gain competit
brand product roch polatuzumab lack willing physician
patient chang new treatment long-stand treatment option
payer us europ could also refus reimburs expens combin
plu revlimid could potenti cost year treatment
addit morphosi current sole sourc incom royalti tremfya could lower
expect due chang highli competit immunolog treatment market risk
morphosi includ develop regulatori disappoint partner out-
licens antibodi two product fail compani valuat would reduc
approxim
pipelin program includ current model
pipelin program exclud current
brand chemic name
type event
event trial detail
date known
specifi
up/down
svb leerink view expect
intern confer malign
collabor annouc
partnership ex us right
mileston payment morphosi
svb leerink llc research compani file
million
royalti mileston po adjust
svb leerink llc research compani file
million
sale
 total revenu
sg total revenu
svb leerink llc research compani file
svb leerink morphosi select balanc sheet cash-flow item
million
cash equival
properti plant equip net
total liabil sharehold equiti
chang asset liabil
chang market secur
proce ipo/off
payment offering/issu cost
proce exercis stock option
chang capit stock net
net chang cash/equival
begin period
end period
 increas work capit
 acquisit licens invest
oper
svb leerink llc reserach compani file
mm
pv flow
equiti
debt
